新天药业(002873) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 3.71% to CNY 35,851,694.95 for the reporting period[8] - Operating income for the period was CNY 238,999,443.50, reflecting a 6.49% increase year-on-year[8] - The company reported a net profit of CNY 61,056,054.17 for the year-to-date, down 12.26% compared to the same period last year[8] - Total operating revenue for Q3 2020 was CNY 238,999,443.50, an increase from CNY 224,431,070.25 in the previous period[40] - Net profit for Q3 2020 reached CNY 35,851,694.95, compared to CNY 34,203,866.45 in the same period last year, reflecting a growth of approximately 4.8%[42] - The company reported a total comprehensive income of CNY 35,851,694.95, compared to CNY 34,567,925.02 in the previous period, indicating an increase of 3.71%[46] - The net profit attributable to the parent company is CNY 83.94 million, an increase of 24.83% from CNY 67.32 million in the same period last year[54] - The total comprehensive income for the period is CNY 83.94 million, compared to CNY 67.32 million in the previous year, indicating a growth of 24.83%[54] Assets and Liabilities - Total assets increased by 29.25% to CNY 1,400,651,996.88 compared to the end of the previous year[8] - The total number of shareholders at the end of the reporting period was 12,247[12] - The company reported a total liability of RMB 622.59 million as of September 30, 2020, compared to RMB 374.89 million at the end of 2019[34] - The company's total equity attributable to shareholders reached CNY 778,060,464.99, up from CNY 707,444,132.04 in the previous year[38] - Total liabilities increased to CNY 589,547,844.43 from CNY 378,985,924.07 year-on-year[38] - The company has a total of RMB 128.00 million in trading financial assets as of September 30, 2020[32] - The company's current assets increased to RMB 737.47 million from RMB 590.06 million year-over-year[32] Cash Flow - Net cash flow from operating activities surged by 2,030.11% to CNY 38,798,247.60[8] - Cash flow from operating activities increased by 163.36% to RMB 100.38 million, primarily due to reduced payments for procurement and taxes[16] - The company reported a significant increase in cash and cash equivalents, reaching CNY 190,534,395.06 compared to CNY 172,345,496.25 in the previous year[37] - The net cash flow from operating activities is CNY 100.38 million, significantly up from CNY 38.12 million in the previous period, marking an increase of 163.5%[57] - The net cash flow from financing activities is ¥250,204,230.52, a recovery from a negative cash flow of -¥23,797,531.83 in the previous period[61] Shareholder Information - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 44.02% of the shares[12] - The company has completed a share buyback of 1,582,500 shares, accounting for 1.35% of total share capital, at a total cost of approximately RMB 25.50 million[18] Research and Development - Research and development expenses decreased by 72.29% to RMB 5.54 million, mainly due to the capitalization of eligible R&D expenditures[16] - Research and development expenses rose significantly to CNY 7,739,072.59, up 69.8% from CNY 4,559,670.51 in the previous year[45] - Research and development expenses decreased to CNY 11.95 million from CNY 18.69 million, a reduction of 36.1%[52] Financial Investments - The company reported investment income of CNY 35 million, a substantial increase from CNY 2 million in the previous period[52] - The company has invested RMB 55.01 million in the Chinese medicine preparation capacity enhancement project, achieving an investment progress of 106.55%[24] - The company has allocated RMB 12.80 million of idle raised funds for purchasing financial products, which are not yet due for redemption[24] Financial Standards and Audits - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[70] - The company has implemented new revenue and leasing standards starting in 2020, which may impact future financial reporting[70]